Compression Therapy Devices MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ProductBy ApplicationBy IndicationBy Distribution Channel

Compression therapy devices apply controlled external pressure to the limbs to support venous return, reduce swelling and lower the risk of blood clots, and range from graduated compression stockings and multi-layer bandaging systems to programmable pneumatic compression pumps and adhesive compression tapes. They are prescribed and used by vascular surgeons, wound-care clinicians, physiotherapists and hospital nursing staff for conditions including chronic venous insufficiency, lymphedema, deep vein thrombosis prevention and post-surgical recovery, and are also purchased directly by patients managing these conditions at home.

USD 4.41 billion of revenue was recorded in the compression therapy devices market compression therapy devices market in 2025. By 2034 the figure reaches USD 9.34 billion, a compound annual growth rate of 8.71% through the forecast period, along a series that runs USD 3.3 billion in 2020, USD 4.18 billion in 2024, USD 4.79 billion in 2026 and USD 6.69 billion in 2030.

The type mix shifts over the period. Static Compression Therapy is the largest line in 2025 at USD 2.58 billion, a 58.4% share, moving to USD 4.86 billion and 52% by 2034. Dynamic Compression Therapy grows fastest at 10.64%, taking its share from 36.6% to 43%, while Static Compression Therapy grows slowest at 7.34%. The lines gaining share are Dynamic Compression Therapy. Static Compression Therapy and Other lose share without losing revenue.

The product split puts Compression Stockings first, at USD 1.5 billion and 34.01% of revenue in 2025, rising to USD 2.8 billion and 29.98% in 2034. Compression Pumps grows faster at 12.09% against 7.19%, moving from 22% of revenue to 29.01% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 37.5% of 2025 revenue, worth USD 1.66 billion and reaching USD 3.27 billion by 2034. Europe follows at 26.6%, moving from USD 1.17 billion to USD 2.24 billion, and Middle East and Africa is the smallest at 4.2%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, three type lines and five segmentation axes across a fifteen-year window.

• The compression therapy devices market compression therapy devices market moves from USD 3.3 billion in 2020 to USD 4.41 billion in 2025 and USD 9.34 billion by 2034, the forecast period compounding at 8.71% a year.
• The largest line by type is Static Compression Therapy, worth USD 2.58 billion and 58.4% of revenue in 2025, rising to USD 4.86 billion and 52% by 2034.
• Dynamic Compression Therapy is the fastest-growing line at 10.64%, lifting its share from 36.6% in 2025 to 43% in 2034 and its revenue from USD 1.61 billion to USD 4.02 billion.
• The bull case puts 2034 revenue at USD 10.18 billion and the bear case at USD 8.5 billion, either side of the USD 9.34 billion base case, each with its own stated assumption in the full report.
• The largest region is North America, generating USD 1.66 billion in 2025 (37.5% of the global total) and USD 3.27 billion by 2034, ahead of Europe at 26.6%.
• 85% of North America's base-year revenue comes from the United States alone: USD 1.41 billion in 2025, rising to USD 2.78 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Read across the forecast period, the compression therapy devices market compression therapy devices market shows movement in three places: type composition, regional weight, and the 8.71% rate applied to the whole.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

Dynamic Compression Therapy grows faster than Static Compression Therapy. 10.64% against 7.34%: that gap, between Dynamic Compression Therapy and Static Compression Therapy, is the largest on the type axis. By 2034 the two sit at 43% and 52% of revenue, against 36.6% and 58.4% in 2025. In absolute terms Dynamic Compression Therapy rises from USD 1.61 billion to USD 4.02 billion, while Static Compression Therapy rises from USD 2.58 billion to USD 4.86 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 25.5% of revenue in 2025 to 30% in 2034, worth USD 1.12 billion rising to USD 2.8 billion; Latin America moves from 6.2% of revenue in 2025 to 6.5% in 2034, worth USD 0.27 billion rising to USD 0.61 billion; Middle East and Africa moves from 4.2% of revenue in 2025 to 4.5% in 2034, worth USD 0.19 billion rising to USD 0.42 billion. The offsetting side is North America at 37.5% moving to 35%, Europe at 26.6% moving to 24%, none of which contracts. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

The series never breaks trajectory. Year by year the total runs USD 3.3 billion in 2020, USD 4.18 billion in 2024, USD 4.41 billion in 2025, USD 4.79 billion in 2026, USD 6.69 billion in 2030 and USD 9.34 billion in 2034. No year breaks the trajectory, and the 8.71% forecast rate compares with 5.97% recorded over 2020-2025, a continuation rather than an inflection. The risk in the number sits in the mix assumptions rather than in whether the market grows at all, which is where the type and regional sections come in.

Growth is concentrated in Dynamic Compression Therapy

The 8.71% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

Downside case: USD 8.5 billion rather than USD 9.34 billion by 2034

What the bull case turns on

Revenue is concentrated in Static Compression Therapy

USD 1.66 billion of 2025 revenue is generated in North America, 37.5% of the compression therapy devices market compression therapy devices market on the way to USD 3.27 billion by 2034. Among the five regions it ranks first by revenue in both years.

Its share moves to 35% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Static Compression Therapy the largest line at 58.4% of 2025 revenue and Dynamic Compression Therapy the fastest-growing at 10.64%. Per-axis and per-country detail for North America sits in the full report.

85% of North America's base-year revenue comes from the United States; USD 1.41 billion, rising to USD 2.78 billion by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country rather than with a spread of them. Against regional totals of USD 1.66 billion in 2025 and USD 3.27 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in the United States is the global one: 58.4% of 2025 revenue in Static Compression Therapy, 52% by 2034, against 10.64% growth in Dynamic Compression Therapy taking it from 36.6% to 43%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The United States carries its own type breakdown in the full report.

In the United States, compression therapy devices are regulated by the Food and Drug Administration as medical devices, with intermittent pneumatic compression systems typically classified as Class II devices subject to premarket notification review demonstrating substantial equivalence to a legally marketed predicate. Manufacturers must comply with the FDA's Quality System Regulation for design and production controls, register their establishment, list their devices, and ensure labeling meets FDA requirements for indications for use, warnings, and contraindications. Electrical and mechanical components must conform to recognized consensus standards for medical electrical equipment safety, and any promotional claims regarding therapeutic benefit must be supported by clinical evidence acceptable to the agency.

Competition in the United States runs between the suppliers this study tracks: Mölnlycke Health Care AB, 3M, Arjo, Brownmed, Inc., Essity Aktiebolag (publ), Cardinal Health, Daesung Maref Co. Ltd, AIROS Medical, Inc., Enovis (DJO Global, Inc), FlowAid Medical Technologies, Avanos Medical, Inc., Julius Zorn, Inc., Lohmann & Rauscher GmbH & Co. KG, Medi GmbH & Co. KG, TONUS ELAST SIA, Medline Industries, Inc., Paul Hartmann AG, SIGVARIS GROUP, Smith & Nephew, Stryker, Tactile Medical, Thuasne SAS and Zimmer Biomet. The commercially relevant division is 58.4% of 2025 revenue in Static Compression Therapy, where the volume is, against 10.64% growth in Dynamic Compression Therapy, where share moves. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.

Within North America, Canada accounts for 15% of regional revenue and 5.7% of the global total, worth USD 0.25 billion in 2025 and USD 0.49 billion by 2034.

USD 1.17 billion of 2025 revenue is generated in Europe, 26.6% of the compression therapy devices market compression therapy devices market rising to USD 2.24 billion in 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 24%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Static Compression Therapy leads here as it does globally, at 58.4% of 2025 revenue, and Dynamic Compression Therapy again grows fastest at 10.64%. Per-axis and per-country detail for Europe sits in the full report.

The largest single market in Europe is Germany, at USD 0.37 billion in 2025 and USD 0.72 billion in 2034. It accounts for 31.6% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 1.17 billion in 2025 and USD 2.24 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Static Compression Therapy at 58.4% of 2025 revenue, easing to 52% by 2034, and the fastest is Dynamic Compression Therapy at 10.64%, from 36.6% to 43%. Its 31.6% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

In Germany, compression therapy devices fall under the European Union's Medical Device Regulation, administered domestically through the Bundesinstitut für Arzneimittel und Medizinprodukte as the competent authority. Devices must undergo a conformity assessment appropriate to their risk classification, typically involving a Notified Body for anything beyond the lowest class, before receiving CE marking that permits sale across the European Economic Area. Manufacturers must maintain a technical file demonstrating compliance with essential safety and performance requirements, implement a post-market surveillance system, and ensure labeling and instructions for use are provided in German alongside the required languages. Compression garments and pneumatic compression systems intended for medical use are also expected to conform to relevant harmonized standards for biocompatibility and electrical safety.

In Germany the field is Mölnlycke Health Care AB, 3M, Arjo, Brownmed, Inc., Essity Aktiebolag (publ), Cardinal Health, Daesung Maref Co. Ltd, AIROS Medical, Inc., Enovis (DJO Global, Inc), FlowAid Medical Technologies, Avanos Medical, Inc., Julius Zorn, Inc., Lohmann & Rauscher GmbH & Co. KG, Medi GmbH & Co. KG, TONUS ELAST SIA, Medline Industries, Inc., Paul Hartmann AG, SIGVARIS GROUP, Smith & Nephew, Stryker, Tactile Medical, Thuasne SAS and Zimmer Biomet. The commercially relevant division is 58.4% of 2025 revenue in Static Compression Therapy, where the volume is, against 10.64% growth in Dynamic Compression Therapy, where share moves.

5.9% of global revenue is generated in France; USD 0.26 billion in 2025, reaching USD 0.49 billion in 2034, and 22.2% of Europe.

The United Kingdom is sized at USD 0.23 billion in 2025, rising to USD 0.45 billion by 2034; 5.2% of global revenue and 19.7% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

25.5% of the compression therapy devices market compression therapy devices market sits in Asia Pacific in 2025, worth USD 1.12 billion with USD 2.8 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 30%, on growth above the market's own 8.71%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 58.4% of 2025 revenue in Static Compression Therapy, fastest growth of 10.64% in Dynamic Compression Therapy. Asia Pacific is reported axis by axis and country by country in the full study.

The largest single market in Asia Pacific is China, at USD 0.45 billion in 2025 and USD 1.12 billion in 2034. At 40.2% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 1.12 billion to USD 2.8 billion over the same period, and this is the market carrying the country-level detail in the full report.

The type pattern in China is the global one: 58.4% of 2025 revenue in Static Compression Therapy, 52% by 2034, against 10.64% growth in Dynamic Compression Therapy taking it from 36.6% to 43%. Its 40.2% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by type separately.

In China, compression therapy devices are regulated by the National Medical Products Administration, which classifies medical devices by risk and requires registration before market entry. Intermittent pneumatic compression devices generally fall into an intermediate risk category, requiring clinical evaluation data, a domestic agent for foreign manufacturers, and compliance with national and industry standards governing electrical safety, biocompatibility, and performance. Products must carry a valid registration certificate, and labeling and instructions must be presented in Chinese with required warnings and usage guidance. Manufacturing facilities are subject to quality management system inspection aligned with national good manufacturing practice requirements before and after approval is granted.

Competition in China runs between the suppliers this study tracks: Mölnlycke Health Care AB, 3M, Arjo, Brownmed, Inc., Essity Aktiebolag (publ), Cardinal Health, Daesung Maref Co. Ltd, AIROS Medical, Inc., Enovis (DJO Global, Inc), FlowAid Medical Technologies, Avanos Medical, Inc., Julius Zorn, Inc., Lohmann & Rauscher GmbH & Co. KG, Medi GmbH & Co. KG, TONUS ELAST SIA, Medline Industries, Inc., Paul Hartmann AG, SIGVARIS GROUP, Smith & Nephew, Stryker, Tactile Medical, Thuasne SAS and Zimmer Biomet. Two different problems sit on the same axis: holding Static Compression Therapy at 58.4% of 2025 revenue, and taking Dynamic Compression Therapy while it grows at 10.64%.

Japan is sized at USD 0.28 billion in 2025, rising to USD 0.7 billion by 2034; 6.4% of global revenue and 25% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

India is sized at USD 0.17 billion in 2025, rising to USD 0.42 billion by 2034; 3.9% of global revenue and 15.2% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Latin America holds 6.2% of the compression therapy devices market compression therapy devices market in 2025, worth USD 0.27 billion rising to USD 0.61 billion in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 6.5%, because it outgrows the market's 8.71%; the revenue added here is disproportionate to where the region started.

Within the region the type split tracks the global one; 58.4% of 2025 revenue in Static Compression Therapy, fastest growth of 10.64% in Dynamic Compression Therapy. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

The largest single market in Latin America is Brazil, at USD 0.12 billion in 2025 and USD 0.27 billion in 2034. 44.4% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.27 billion and USD 0.61 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The type pattern in Brazil is the global one: 58.4% of 2025 revenue in Static Compression Therapy, 52% by 2034, against 10.64% growth in Dynamic Compression Therapy taking it from 36.6% to 43%. Because the country carries 44.4% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Brazil carries its own type breakdown in the full report.

In Brazil, compression therapy devices are regulated by the Agência Nacional de Vigilância Sanitária, which oversees classification, registration, and market authorization of medical devices sold domestically. Manufacturers or their local registration holders must submit technical documentation demonstrating safety and performance, obtain the applicable product registration or notification depending on risk classification, and comply with Good Manufacturing Practice certification for the production site. Labeling must appear in Portuguese and include instructions for use, contraindications, and storage conditions. Electrical and mechanical safety must conform to recognized national and international standards, and any therapeutic claims made in marketing materials must align with the approved indications on file with the regulator.

Competition in Brazil runs between the suppliers this study tracks: Mölnlycke Health Care AB, 3M, Arjo, Brownmed, Inc., Essity Aktiebolag (publ), Cardinal Health, Daesung Maref Co. Ltd, AIROS Medical, Inc., Enovis (DJO Global, Inc), FlowAid Medical Technologies, Avanos Medical, Inc., Julius Zorn, Inc., Lohmann & Rauscher GmbH & Co. KG, Medi GmbH & Co. KG, TONUS ELAST SIA, Medline Industries, Inc., Paul Hartmann AG, SIGVARIS GROUP, Smith & Nephew, Stryker, Tactile Medical, Thuasne SAS and Zimmer Biomet. Static Compression Therapy, at 58.4% of 2025 revenue, is where the volume sits, and Dynamic Compression Therapy, growing at 10.64%, is where position changes hands over the forecast period.

1.8% of global revenue is generated in Mexico; USD 0.08 billion in 2025, reaching USD 0.18 billion in 2034, and 29.6% of Latin America.

4.2% of the compression therapy devices market compression therapy devices market sits in Middle East and Africa in 2025, worth USD 0.19 billion with USD 0.42 billion projected for 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 4.5% over the forecast period, so the region grows faster than the market's 8.71% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 58.4% of 2025 revenue in Static Compression Therapy, fastest growth of 10.64% in Dynamic Compression Therapy. The full report breaks Middle East and Africa out along every axis and by country.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.07 billion in 2025 and USD 0.15 billion in 2034. It accounts for 36.8% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.19 billion to USD 0.42 billion over the same period, and this is the market carrying the country-level detail in the full report.

Saudi Arabia buys along the same lines as the market globally; Static Compression Therapy first at 58.4% of 2025 revenue and 52% in 2034, Dynamic Compression Therapy fastest at 10.64% on a share moving from 36.6% to 43%. With 36.8% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, compression therapy devices are regulated by the Saudi Food and Drug Authority under its medical device framework, which follows international risk-based classification principles. Suppliers must obtain a medical device marketing authorization prior to sale, typically relying on an authorized local representative to manage registration, and must demonstrate conformity with recognized international safety and performance standards, often accepted through prior approvals from reference regulatory authorities. Establishment licensing is required for local distributors and importers, and labeling must be provided in Arabic alongside English, covering intended use, warnings, and handling instructions. Post-market vigilance reporting obligations apply once a device is placed on the market.

Competition in Saudi Arabia runs between the suppliers this study tracks: Mölnlycke Health Care AB, 3M, Arjo, Brownmed, Inc., Essity Aktiebolag (publ), Cardinal Health, Daesung Maref Co. Ltd, AIROS Medical, Inc., Enovis (DJO Global, Inc), FlowAid Medical Technologies, Avanos Medical, Inc., Julius Zorn, Inc., Lohmann & Rauscher GmbH & Co. KG, Medi GmbH & Co. KG, TONUS ELAST SIA, Medline Industries, Inc., Paul Hartmann AG, SIGVARIS GROUP, Smith & Nephew, Stryker, Tactile Medical, Thuasne SAS and Zimmer Biomet. Volume sits in Static Compression Therapy at 58.4% of 2025 revenue; movement sits in Dynamic Compression Therapy at 10.64% growth.

1.1% of global revenue is generated in South Africa; USD 0.05 billion in 2025, reaching USD 0.11 billion in 2034, and 26.3% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, product, application, indication, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.